Physician identification of opioid diversion: A difficult diagnosis
DOI:
https://doi.org/10.5055/jom.2012.0090Abstract
-References
Sloan PA: Oxymorphone in the management of pain. Ther Clin Risk Manage. 2008; 4: 1-11.
U.S. Prescription drug sales grow slowly; hydrocodone most prescribed. IMS Health. 2009. Available at www.seekingalpha.com/article/128003-u-s-prescription-drug-sales-grow-slowlyhydrocodone-most-prescribed. Accessed January 3, 2012.
Substance Abuse and Mental Health Services Administration: Results from the 2008 National Survey on Drug Use and Health: National Findings. Office of Applied Studies, NSDUH Series H-36, HHS Publication No. SMA 09-4434. Rockville, MD, 2009.
Laws of Florida. Chapter 2011-141. Committee Substitute for House Bill No. 7095. Available at http://laws.flrules.org/2011/141. Accessed January 10, 2012.
Volkow ND, McLellan TA: Curtailing diversion and abuse of opioid analgesics without jeopardizing pain treatment. JAMA. 2011; 305(13): 1346-1347.
Christo PJ, Manchikanti L, Ruan X, Bottros M, Hansen H, Solanki DR, et al. Urine drug testing in chronic pain. Pain Physician. 2011; 14(2): 123-143.
Von Seggern RL, Fitzgerald CP, Adelman LC, et al.: Laboratory monitoring of OxyContin (oxycodone): clinical pitfalls. Headache. 2004; 44(1): 44-47.
Reisfield GM, Goldberger BA, Bertholf RL: “False-positive” and “false-negative” test results in clinical urine drug testing. Bioanalysis. 2009; 1(5): 937-952.
Reisfield GM, Webb FJ, Bertholf RL, et al.: Family physicians’ proficiency in urine drug test interpretation. J Opioid Manag. 2007; 3(6): 333-337.
Reisfield GM, Bertholf R, Barkin RL, et al.: Urine drug test interpretation: what do physicians know? J Opioid Manag. 2007; 3(2): 80-86.
Downloads
Published
How to Cite
Issue
Section
License
Copyright 2005-2024, Weston Medical Publishing, LLC
All Rights Reserved